China and India, against the backdrop of a slowing economy, protectionism, uncertain global politics and new technologies, are working purposefully to build their bilateral relationship, with particular emphasis on trade.
17 cancer drugs were slashed and these were included in the Chinese national medical insurance catalogue.
India, as the world’s dominant generic drug producers, is already selling to the EU. Swift regulatory approvals in China to Indian drug companies would contribute to lowering current drug prices in China and making the prices competitive. According to Chinese Foreign Ministry spokeswoman Hua Chunying:
“The relevant departments from both side have formulated specific measures on promoting China-India pharmaceutical trade cooperation and granting greater access to drugs from India”.